The Repercussions of Medicare's New Hepatitis C Push

Could Medicare's new hepatitis c screening coverage make a big difference to investors?

Jun 8, 2014 at 1:31PM

This week, the Centers for Medicare & Medicaid Services, or CMS, announced a big shift in health policy. CMS intends to cover screening for hepatitis C for members who fall into either of two buckets: those who are considered to be at high risk for the disease (those who injected illegal drugs or had a blood transfusion before 1992), and anyone born between 1945 and 1965. This could significantly increase the number of people diagnosed with hepatitis C in the United States at a time when major cures are finally hitting the market.

We're investors, so the big question for us is simple: Who benefits? What stocks are poised to profit from this big trend?

Gilead Sciences (NASDAQ:GILD) is the first name that comes to everyone's mind. After all, Gilead's drug Sovaldi, which is a single pill that is interferon-free for type 2 and 3 hepatitis C, sold $2.3 billion last quarter, its first full quarter on the market, shattering previous drug uptake records and almost doubling Gilead's top line year over year. What's more, physicians (off-label) can prescribe Sovaldi with Johnson & Johnson's (NYSE:JNJ) Olysio to create an interferon-free combination for type 1 hepatitis C. And with the nasty, flu-like symptoms interferon can cause, that's a big plus.

Of course, there are competitors coming to market as well -- AbbVie (NYSE:ABBV) has a six-pill combination drug that is moving toward its final regulatory hurdles, while further back Bristol-Myers Squibb and Merck have their own potential competitors pushing through trials and posting strong data as well. With the market to itself right now but looking increasingly crowded over the next few years, can Gilead make its billions off Sovaldi, or will competition reduce prices and profitability?

In the video below, from Where The Money Is, the Motley Fool's investing show, health care analysts Michael Douglass and David Williamson talk through the changes and investors' opportunity in this space.

Will this stock be your next multi-bagger?
Give us five minutes and we'll show how you could own the best stock for 2014. Every year, The Motley Fool's chief investment officer hand-picks one stock with outstanding potential. But it's not just any run-of-the-mill company. It's a stock perfectly positioned to cash in on one of the upcoming year's most lucrative trends. Last year his pick skyrocketed 134%. And previous top picks have gained upwards of 908%, 1,252% and 1,303% over the subsequent years! Believe me, you don't want to miss what could be his biggest winner yet! Just click here to download your free copy of "The Motley Fool's Top Stock for 2014" today.

David Williamson owns shares of AbbVie, Merck, and Johnson & Johnson. Michael Douglass has no position in any stocks mentioned. The Motley Fool recommends Gilead Sciences and Johnson & Johnson. The Motley Fool owns shares of Gilead Sciences and Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Money to your ears - A great FREE investing resource for you

The best way to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as “binge-worthy finance.”

Feb 1, 2016 at 5:03PM

Whether we're in the midst of earnings season or riding out the market's lulls, you want to know the best strategies for your money.

And you'll want to go beyond the hype of screaming TV personalities, fear-mongering ads, and "analysis" from people who might have your email address ... but no track record of success.

In short, you want a voice of reason you can count on.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich," rated The Motley Fool as the #1 place online to get smarter about investing.

And one of the easiest, most enjoyable, most valuable ways to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as "binge-worthy finance."

Whether you make it part of your daily commute or you save up and listen to a handful of episodes for your 50-mile bike rides or long soaks in a bubble bath (or both!), the podcasts make sense of your money.

And unlike so many who want to make the subjects of personal finance and investing complicated and scary, our podcasts are clear, insightful, and (yes, it's true) fun.

Our free suite of podcasts

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. The show is also heard weekly on dozens of radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable. Rule Breaker Investing and Answers are timeless, so it's worth going back to and listening from the very start; the other three are focused more on today's events, so listen to the most recent first.

All are available for free at

If you're looking for a friendly voice ... with great advice on how to make the most of your money ... from a business with a lengthy track record of success ... in clear, compelling language ... I encourage you to give a listen to our free podcasts.

Head to, give them a spin, and you can subscribe there (at iTunes, Stitcher, or our other partners) if you want to receive them regularly.

It's money to your ears.


Compare Brokers